2-(2,4-DIFLUOROPHENYL)-5-(ETHYLSULFONYL)-1,3,4-OXADIAZOLE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZDOXQFSWHUAPKR-UHFFFAOYSA-N
Smiles	CCS(=O)(=O)c1oc(nn1)c2ccc(F)cc2F
InChI	InChI=1S/C10H8F2N2O3S/c1-2-18(15,16)10-14-13-9(17-10)7-4-3-6(11)5-8(7)12/h3-5H,2H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H8F2N2O3S
Molecular Weight	274.24
AlogP	1.96
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	3.0
Polar Surface Area	81.44
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity
Antibacterial activity against Ralstonia solanacearum assessed as growth inhibition at 500 ug/ml by turbidometer test (beneficial crop tobacco plant)	Ralstonia solanacearum	100.0 %
Antibacterial activity against Ralstonia solanacearum assessed as growth inhibition at 200 ug/ml by turbidometer test (beneficial crop tobacco plant)	Ralstonia solanacearum	92.3 %
Antibacterial activity against Ralstonia solanacearum assessed as growth inhibition by turbidometer test (beneficial crop tobacco plant)	Ralstonia solanacearum	60.3 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2228962
PubChem	56958161

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).